IART
NASDAQIntegra LifeSciences Holdings Corporation
SectorHealth CareIndustryMedical/Dental Instruments
Website
News25/Ratings12
News · 26 weeks34-50%
2025-10-262026-04-19
Mix2390d
- Insider10(43%)
- SEC Filings5(22%)
- Earnings3(13%)
- Leadership2(9%)
- Other2(9%)
- Analyst1(4%)
Latest news
25 items- PRIntegra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, May 5, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the con
- SECIntegra LifeSciences Holdings Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- ANALYSTIntegra downgraded by ArgusArgus downgraded Integra from Buy to Hold
- PRIntegra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix® UtilizationPRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will present new real-world data on PriMatrix® Dermal Scaffold at three major medical conferences in April. The data include new analyses from 985 cases involving 117 surgeons, highlighting the use of PriMatrix, a fetal bovine dermal matrix, across a broad range of wound types, including surgical, traumatic and chronic ulcers, as well as complex wounds with tunneling and undermining features.1,2,3 In addition, a 23-patient case series outlines clinical experience with PriMatrix in support of wound bed readiness in burn injuries, including
- SECSEC Form DEF 14A filed by Integra LifeSciences Holdings CorporationDEF 14A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Integra LifeSciences Holdings CorporationSCHEDULE 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
- PRNeuronetics Appoints Dan Reuvers as President and Chief Executive OfficerMALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin
- INSIDEREVP & PRESIDENT, INTERNATIONAL Singh Harvinder converted options into 20,138 shares and covered exercise/tax liability with 6,652 shares, increasing direct ownership by 61% to 35,422 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDEREVP & President, CSS Mcbreen Michael J. covered exercise/tax liability with 9,601 shares, decreasing direct ownership by 14% to 60,743 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDEREVP & President, TT Davis Robert T. Jr. covered exercise/tax liability with 9,174 shares, decreasing direct ownership by 12% to 66,387 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 1,147 shares, decreasing direct ownership by 3% to 35,453 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDEREVP & Chief Financial Officer Knight Lea Daniels covered exercise/tax liability with 8,089 shares, decreasing direct ownership by 14% to 50,489 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDEREVP & CHRO Veillon-Berteloot Chantal covered exercise/tax liability with 5,420 shares, decreasing direct ownership by 20% to 22,227 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Poul Mojdeh4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Chief Legal Officer & Sec Hutchinson Michael Damon4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- SECSEC Form S-3ASR filed by Integra LifeSciences Holdings CorporationS-3ASR - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- SECSEC Form 10-K filed by Integra LifeSciences Holdings Corporation10-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- SECIntegra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- PRIntegra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial GuidancePRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024. GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024.Adjusted earnings per diluted share were $0.83, compared to $0.97 in the fourth quarter of 2024. Full-Year 2025 Reported revenues were $1,635.2 million, representing an increase of 1.5% on a reported basis and
- PRIntegra LifeSciences Announces Key Executive Leadership AppointmentsPRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development (R&D), including product and technology development, across the company. The company also announced the appointments of Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer. The creation of the chief technology officer (CTO) position underscores Integra's commitment to build
- PRIntegra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webc
- INSIDERSEC Form 4 filed by EVP, Chief Legal Officer & Sec Hutchinson Michael Damon4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hutchinson Michael Damon3 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERPresident & CEO Poul Mojdeh converted options into 1,390 shares and covered exercise/tax liability with 1,390 shares (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- PRIntegra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare ConferencePRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m ET or 11:15 a.m PT A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciencesAt Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance patient outcomes and set new